We hypothesized that treatment with an SSTR2 antagonist (PRL-2903), prior to insulin-induced hypoglycemia, would increase the glucagon response to iatrogenic (i.e., insulin-induced) hypoglycemia. Here, INS is linked to Hypoglycemia.